Health TrialsbyHealthPanel

Myeloma Registry Platform (MYRIAM)

ConditionMultiple Myeloma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsoriOMEDICO AG

About this trial

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

MM requiring systemic (first-, second- or third-line) treatment (closed for first-line / second-line recruitment)

Age ≥ 18 years

Written informed consent

Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment

Disqualifiers

No systemic therapy for myeloma

Patients already enrolled in studies that prohibit any participation in other studies

Trial population

Adult patients with multiple myeloma (MM) requiring systemic treatment

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Routine care as per site standard.

    Other intervention

    Physician's choice according to patient's needs.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Course of treatment (treatment reality)

Documentation of anamnestic data and therapy sequences

Time frame
5 years per patient

Secondary outcomes

1

Best Response

Documentation of response rates per line of treatment.

Time frame
5 years per patient
2

Progression-free survival

Documentation of progression-free survival per line of treatment.

Time frame
5 years per patient
3

Overall survival

Documentation of overall survival time.

Time frame
5 years per patient
4

Health-related quality of life (Patient-reported outcome)

EORTC QLQ-C30 core questionnaire.

Time frame
5 years per patient

Other outcomes

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

Multiple sites all over germanyRecruiting Multiple SitesGermanyGermany

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

iOMEDICO AG

Lead sponsor

Deutsche Studiengruppe Multiples Myelom (DSMM)

Collaborator

Source ClinicalTrials.gov
Apply now